Products

Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.

Connect With Us

Immunotherapy (Checkpoint Inhibitor) (26)

Quick filters: Solid Tumour Hematologic Both Name A-Z Name Z-A

Therapeutic Areas

Sort by

Clear all filters

Molecule	Drug Class / Mechanism	Oncology Type
Pembrolizumab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Pembrolizumab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Nivolumab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Nivolumab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Cemiplimab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Cemiplimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Dostarlimab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Dostarlimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Toripalimab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Toripalimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Sintilimab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Sintilimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Camrelizumab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Camrelizumab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Tislelizumab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Tislelizumab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Penpulimab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Penpulimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Serplulimab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Serplulimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Zimberelimab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Zimberelimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Retifanlimab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Retifanlimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb

Pembrolizumab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Nivolumab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Cemiplimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Dostarlimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Toripalimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Sintilimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Camrelizumab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Tislelizumab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Penpulimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Serplulimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Zimberelimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Retifanlimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb

‹ 1 2 3 ›

Product Range

Company

Global Network

Products

Pembrolizumab

Nivolumab

Cemiplimab

Dostarlimab

Toripalimab

Sintilimab

Camrelizumab

Tislelizumab

Penpulimab

Serplulimab

Zimberelimab

Retifanlimab